A 52-year-old man with metastatic adenocarcinoma of the pancreas is admitted with acute onset of severe abdominal pain, hemoptysis, and hematuria. Laboratory findings show: PT 22 s (control 13 s), aPTT 52 s (control 30 s), fibrinogen 110 mg/dL, platelets 45,000/μL, D-dimer 8000 ng/mL, and hemoglobin drop from 11 g/dL to 8.5 g/dL over 6 hours. Peripheral blood smear shows schistocytes. The patient is currently on no anticoagulation. What is the most appropriate next step?

Explanation

## Clinical Presentation of Cancer-Associated DIC This patient has **overt DIC** secondary to metastatic pancreatic cancer, characterized by: - **Consumption coagulopathy:** prolonged PT/aPTT, low fibrinogen, thrombocytopenia - **Fibrinolysis:** elevated D-dimer, schistocytes on smear (mechanical hemolysis from fibrin strands) - **Bleeding manifestations:** hemoptysis, hematuria, acute abdominal pain (likely GI bleed) - **Rapid decompensation:** Hgb drop of 2.5 g/dL in 6 hours **Key Point:** Adenocarcinomas (especially pancreatic, lung, gastric) are the most common solid tumors causing DIC. They release tissue factor and cancer procoagulant into the circulation. ## Management Hierarchy in Overt DIC **High-Yield:** The management of DIC with active bleeding follows this sequence: 1. **Aggressive supportive transfusion** (FFP, platelets, cryoprecipitate) to replace consumed clotting factors and platelets 2. **Treat the underlying cause** (chemotherapy for malignancy, antibiotics for sepsis, delivery for obstetric DIC) 3. **Anticoagulation is considered ONLY** if: - Bleeding is controlled - Thrombotic manifestations dominate (e.g., acral necrosis, gangrene) - After discussion with hematology/oncology **Clinical Pearl:** In cancer-associated DIC, chemotherapy itself often rapidly improves coagulopathy by reducing tumor burden and tissue factor release. This is the definitive treatment. ## Why Heparin Is Wrong in This Context ```mermaid flowchart TD A[Overt DIC + Active Bleeding]:::outcome --> B{Bleeding controlled?}:::decision B -->|No| C[Transfuse FFP/Plt/Cryo]:::action B -->|Yes| D[Treat underlying cause]:::action D --> E{Thrombotic manifestations?}:::decision E -->|Yes| F[Consider heparin]:::action E -->|No| G[Supportive care only]:::action C --> H[Reassess after transfusion]:::outcome ``` **Warning:** Heparin in active bleeding DIC increases hemorrhage risk without benefit. The patient is already bleeding from multiple sites (hemoptysis, hematuria, GI). Heparin would worsen bleeding and delay the definitive treatment (chemotherapy). ## Supportive Transfusion Protocol | Product | Indication | Target | |---------|-----------|--------| | FFP | PT/aPTT >1.5× control + bleeding | Normalize PT/aPTT | | Cryoprecipitate | Fibrinogen <100 mg/dL + bleeding | Fibrinogen >150 mg/dL | | Platelets | <20,000/μL or active bleeding | >50,000/μL | | RBC | Hgb <7 g/dL or ongoing hemorrhage | Hgb 8–9 g/dL | **Key Point:** Transfuse in this order: FFP → cryoprecipitate → platelets → RBC. Avoid over-transfusion of RBCs (increases viscosity and thrombotic risk).